RLMD Relmada Therapeutics, Inc.

NASDAQ
$2.86

Relmada Therapeutics, Inc. (RLMD) Earnings News

Earnings press releases, previews and reviews for Relmada Therapeutics, Inc. (RLMD), newest first. Our most recent is review: Relmada Beats on Per-Share Loss, but Dilution Drives the Number as 18-Month NDV-01 Data Reveal Its First Progressions.